Symbols / PRQR
PRQR Chart
About
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 162.23M |
| Enterprise Value | 71.84M | Income | -42.57M | Sales | 16.07M |
| Book/sh | 0.64 | Cash/sh | 1.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 166 | IPO | — |
| P/E | — | Forward P/E | -3.28 | PEG | — |
| P/S | 10.09 | P/B | 2.41 | P/C | — |
| EV/EBITDA | -1.65 | EV/Sales | 4.47 | Quick Ratio | 3.30 |
| Current Ratio | 3.36 | Debt/Eq | 28.90 | LT Debt/Eq | — |
| EPS (ttm) | -0.48 | EPS next Y | -0.47 | EPS Growth | — |
| Revenue Growth | -26.80% | Earnings | 2026-03-12 | ROA | -24.02% |
| ROE | -103.76% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -3.87% | Profit Margin | -264.83% | Shs Outstand | 105.35M |
| Shs Float | 64.36M | Short Float | 2.38% | Short Ratio | 3.39 |
| Short Interest | — | 52W High | 3.10 | 52W Low | 1.07 |
| Beta | 0.20 | Avg Volume | 525.39K | Volume | 166.23K |
| Target Price | $8.88 | Recom | Strong_buy | Prev Close | $1.51 |
| Price | $1.54 | Change | 1.99% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.88
Mean price target
2. Current target
$1.54
Latest analyst target
3. DCF / Fair value
$-5.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.54
Low
$4.00
High
$14.00
Mean
$8.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-04 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-06-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2025-06-27 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2025-05-13 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-04-29 | init | Evercore ISI Group | — → Outperform | $5 |
| 2025-03-14 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-03-14 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-12 | init | Jones Trading | — → Buy | $11 |
| 2024-12-12 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-12-12 | main | Chardan Capital | Buy → Buy | $4 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-29 | up | Raymond James | Outperform → Strong Buy | $14 |
| 2024-05-10 | main | Chardan Capital | Buy → Buy | $3 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-18 | main | Citigroup | Neutral → Neutral | $2 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-14 | main | Chardan Capital | Buy → Buy | $3 |
| 2023-11-08 | main | Raymond James | Outperform → Outperform | $4 |
- Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail Wed, 25 Feb 2026 15
- Co-founder among 2 ProQR directors set to leave board at 2026 AGM - Stock Titan Mon, 09 Feb 2026 08
- ProQR Therapeutics: Not A Needle Mover Just Yet - Seeking Alpha Sat, 06 Sep 2025 07
- ProQR Announces Planned Changes to Board Composition - GlobeNewswire Mon, 09 Feb 2026 08
- ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat ue, 10 Feb 2026 08
- ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st ue, 15 Jul 2025 07
- ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Nigeria hu, 08 Jan 2026 15
- ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk - Sahm Mon, 24 Nov 2025 08
- Why PRQR stock could benefit from AI revolution - Weekly Stock Analysis & Safe Entry Trade Reports - mfd.ru Fri, 20 Feb 2026 08
- symbol__ Stock Quote Price and Forecast - CNN Mon, 12 Feb 2024 10
- ProQR Announces First Quarter 2025 Operating and Financial Results - Stock Titan hu, 08 May 2025 07
- ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance Sat, 09 Aug 2025 07
- Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st ue, 13 Jan 2026 08
- RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg.com Wed, 16 Oct 2024 07
- Will PRQR benefit from geopolitical trends - 2025 Earnings Surprises & Accurate Technical Buy Alerts - mfd.ru Fri, 20 Feb 2026 22
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -49.00 | 13.90K | 707.07K | 546.75K |
| TaxRateForCalcs | 0.01 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -24.11M | -28.73M | -59.83M | -56.97M |
| TotalUnusualItems | -7.00K | 4.63M | 3.37M | 2.02M |
| TotalUnusualItemsExcludingGoodwill | -7.00K | 4.63M | 3.37M | 2.02M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -27.76M | -28.12M | -64.42M | -60.74M |
| ReconciledDepreciation | 2.76M | 2.51M | 2.52M | 2.33M |
| EBITDA | -24.12M | -24.10M | -56.46M | -54.95M |
| EBIT | -26.88M | -26.61M | -58.98M | -57.28M |
| NetInterestIncome | 2.17M | 1.39M | -5.02M | -3.40M |
| InterestExpense | 1.08M | 1.20M | 5.13M | 3.40M |
| InterestIncome | 3.25M | 2.59M | 106.00K | 5.00K |
| NormalizedIncome | -27.76M | -32.74M | -67.08M | -62.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -27.76M | -28.12M | -64.42M | -60.74M |
| TotalExpenses | 49.38M | 41.30M | 68.75M | 58.55M |
| TotalOperatingIncomeAsReported | -30.47M | -31.86M | -65.16M | -57.21M |
| DilutedAverageShares | 86.09M | 81.01M | 71.64M | 64.18M |
| BasicAverageShares | 86.09M | 81.01M | 71.64M | 64.18M |
| DilutedEPS | -0.32 | -0.35 | -0.90 | -0.96 |
| BasicEPS | -0.32 | -0.35 | -0.90 | -0.96 |
| DilutedNIAvailtoComStockholders | -27.76M | -28.12M | -64.42M | -60.74M |
| NetIncomeCommonStockholders | -27.76M | -28.12M | -64.42M | -60.74M |
| NetIncome | -27.76M | -28.12M | -64.42M | -60.74M |
| MinorityInterests | 0.00 | -384.00K | -220.00K | 59.00K |
| NetIncomeIncludingNoncontrollingInterests | -27.76M | -27.73M | -64.20M | -60.80M |
| NetIncomeContinuousOperations | -27.76M | -27.73M | -64.20M | -60.80M |
| TaxProvision | -197.00K | -78.00K | 96.00K | 117.00K |
| PretaxIncome | -27.96M | -27.81M | -64.11M | -60.68M |
| OtherIncomeExpense | 338.00K | 5.59M | 6.07M | -72.00K |
| OtherNonOperatingIncomeExpenses | 345.00K | 953.00K | 2.71M | -1.88M |
| SpecialIncomeCharges | 0.00 | 4.89M | -1.39M | 514.00K |
| GainOnSaleOfPPE | 0.00 | 2.93M | 0.00 | 0.00 |
| GainOnSaleOfBusiness | 0.00 | 92.00K | 0.00 | 514.00K |
| OtherSpecialCharges | -1.87M | 1.39M | ||
| EarningsFromEquityInterest | 0.00 | 0.00 | -8.00K | -217.00K |
| GainOnSaleOfSecurity | -7.00K | -255.00K | 4.76M | 1.51M |
| NetNonOperatingInterestIncomeExpense | 2.17M | 1.39M | -5.02M | -3.40M |
| InterestExpenseNonOperating | 1.08M | 1.20M | 5.13M | 3.40M |
| InterestIncomeNonOperating | 3.25M | 2.59M | 106.00K | 5.00K |
| OperatingIncome | -30.47M | -34.79M | -65.16M | -57.21M |
| OperatingExpense | 49.38M | 41.30M | 68.75M | 58.55M |
| OtherOperatingExpenses | -640.00K | -80.00K | -765.00K | -1.04M |
| ResearchAndDevelopment | 36.36M | 25.15M | 50.87M | 42.22M |
| SellingGeneralAndAdministration | 13.66M | 16.24M | 18.65M | 17.37M |
| GeneralAndAdministrativeExpense | 13.66M | 16.24M | 18.65M | 17.37M |
| OtherGandA | 13.66M | 16.24M | 18.65M | 17.37M |
| TotalRevenue | 18.91M | 6.51M | 3.59M | 1.33M |
| OperatingRevenue | 18.91M | 6.51M | 3.59M | 1.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 2.50M | 2.89M | 3.43M | 3.57M |
| OrdinarySharesNumber | 105.21M | 81.35M | 80.82M | 71.29M |
| ShareIssued | 107.71M | 84.25M | 84.25M | 74.87M |
| TotalDebt | 17.22M | 19.73M | 21.97M | 60.37M |
| TangibleBookValue | 88.56M | 41.39M | 67.06M | 113.83M |
| InvestedCapital | 93.14M | 45.68M | 73.84M | 157.92M |
| WorkingCapital | 114.94M | 86.78M | 133.47M | 163.89M |
| NetTangibleAssets | 88.56M | 41.39M | 67.06M | 113.83M |
| CapitalLeaseObligations | 12.63M | 15.44M | 15.20M | 16.28M |
| CommonStockEquity | 88.56M | 41.39M | 67.06M | 113.83M |
| TotalCapitalization | 88.56M | 45.68M | 71.34M | 153.15M |
| TotalEquityGrossMinorityInterest | 88.56M | 41.39M | 66.68M | 113.23M |
| MinorityInterest | 0.00 | 0.00 | -384.00K | -604.00K |
| StockholdersEquity | 88.56M | 41.39M | 67.06M | 113.83M |
| GainsLossesNotAffectingRetainedEarnings | 27.60M | 25.98M | 30.26M | 30.30M |
| RetainedEarnings | -427.16M | -400.85M | -379.11M | -317.77M |
| AdditionalPaidInCapital | 483.81M | 412.89M | 412.54M | 398.31M |
| CapitalStock | 4.31M | 3.37M | 3.37M | 3.00M |
| CommonStock | 4.31M | 3.37M | 3.37M | 3.00M |
| TotalLiabilitiesNetMinorityInterest | 79.40M | 96.49M | 104.64M | 96.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 40.50M | 62.29M | 83.65M | 68.75M |
| NonCurrentDeferredLiabilities | 29.43M | 44.17M | 65.57M | 14.69M |
| NonCurrentDeferredRevenue | 29.43M | 44.17M | 65.57M | 14.69M |
| LongTermDebtAndCapitalLeaseObligation | 11.07M | 18.12M | 18.08M | 54.07M |
| LongTermCapitalLeaseObligation | 11.07M | 13.83M | 13.81M | 14.75M |
| LongTermDebt | 4.29M | 4.27M | 39.32M | |
| CurrentLiabilities | 38.90M | 34.20M | 20.99M | 27.60M |
| OtherCurrentLiabilities | 9.32M | 8.82M | 9.95M | 14.76M |
| CurrentDeferredLiabilities | 21.94M | 20.57M | 5.64M | 5.12M |
| CurrentDeferredRevenue | 21.94M | 20.57M | 5.64M | 5.12M |
| CurrentDebtAndCapitalLeaseObligation | 6.15M | 1.61M | 3.89M | 6.30M |
| CurrentCapitalLeaseObligation | 1.57M | 1.61M | 1.39M | 1.53M |
| CurrentDebt | 4.58M | 2.50M | 4.77M | |
| OtherCurrentBorrowings | 4.58M | 2.50M | 4.77M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | |||
| PayablesAndAccruedExpenses | 1.49M | 3.20M | 1.51M | 1.42M |
| Payables | 1.49M | 3.20M | 1.51M | 1.42M |
| TotalTaxPayable | 1.48M | 1.66M | 1.12M | 1.23M |
| AccountsPayable | 16.00K | 1.54M | 392.00K | 191.00K |
| TotalAssets | 167.96M | 137.88M | 171.32M | 209.58M |
| TotalNonCurrentAssets | 14.11M | 16.90M | 16.86M | 18.10M |
| InvestmentsAndAdvances | 0.00 | 0.00 | 621.00K | 629.00K |
| InvestmentinFinancialAssets | 0.00 | 0.00 | 621.00K | 621.00K |
| LongTermEquityInvestment | 0.00 | 8.00K | ||
| InvestmentsinAssociatesatCost | 0.00 | 8.00K | ||
| NetPPE | 14.11M | 16.90M | 16.24M | 17.47M |
| AccumulatedDepreciation | -17.96M | -15.20M | -12.87M | -10.35M |
| GrossPPE | 32.07M | 32.09M | 29.11M | 27.82M |
| OtherProperties | 8.28M | 7.32M | 6.25M | 5.59M |
| Properties | 23.79M | 24.77M | 22.86M | 22.23M |
| CurrentAssets | 153.84M | 120.99M | 154.46M | 191.48M |
| PrepaidAssets | 2.41M | 793.00K | 2.45M | 3.14M |
| Receivables | 2.03M | 1.27M | 57.24M | 823.00K |
| OtherReceivables | 1.34M | 745.00K | 56.63M | 268.00K |
| TaxesReceivable | 690.00K | 523.00K | 607.00K | 555.00K |
| CashCashEquivalentsAndShortTermInvestments | 149.41M | 118.92M | 94.78M | 187.52M |
| CashAndCashEquivalents | 149.41M | 118.92M | 94.78M | 187.52M |
| CashEquivalents | 75.21M | 59.15M | 0.00 | |
| CashFinancial | 74.20M | 59.77M | 94.78M | 187.52M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.81M | 20.18M | -69.22M | -26.50M |
| RepaymentOfDebt | -1.58M | -2.63M | -45.05M | -820.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 27.66M | |
| IssuanceOfCapitalStock | 71.64M | 0.00 | 14.12M | 108.48M |
| CapitalExpenditure | -1.42M | -1.37M | -708.00K | -484.00K |
| EndCashPosition | 149.41M | 118.92M | 94.78M | 187.52M |
| BeginningCashPosition | 118.92M | 94.78M | 187.52M | 75.84M |
| EffectOfExchangeRateChanges | 673.00K | 599.00K | 7.35M | 1.29M |
| ChangesInCash | 29.81M | 23.55M | -100.10M | 110.39M |
| FinancingCashFlow | 70.28M | -2.27M | -30.89M | 136.83M |
| CashFlowFromContinuingFinancingActivities | 70.28M | -2.27M | -30.89M | 136.83M |
| ProceedsFromStockOptionExercised | 223.00K | 354.00K | 34.00K | 1.52M |
| NetCommonStockIssuance | 71.64M | 0.00 | 14.12M | 108.48M |
| CommonStockIssuance | 71.64M | 0.00 | 14.12M | 108.48M |
| NetIssuancePaymentsOfDebt | -1.58M | -2.63M | -45.05M | 26.84M |
| NetLongTermDebtIssuance | -1.58M | -2.63M | -45.05M | 26.84M |
| LongTermDebtPayments | -1.58M | -2.63M | -45.05M | -820.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 27.66M | |
| InvestingCashFlow | -4.07M | 4.28M | -702.00K | -425.00K |
| CashFlowFromContinuingInvestingActivities | -4.07M | 4.28M | -702.00K | -425.00K |
| NetOtherInvestingChanges | -2.65M | -2.35M | ||
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 0.00 | |
| SaleOfInvestment | 17.00M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -17.00M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | 7.94M | 0.00 | 0.00 |
| SaleOfIntangibles | 0.00 | 7.94M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -1.42M | -1.31M | -702.00K | -425.00K |
| SaleOfPPE | 0.00 | 60.00K | 6.00K | 59.00K |
| PurchaseOfPPE | -1.42M | -1.37M | -708.00K | -484.00K |
| OperatingCashFlow | -36.39M | 21.55M | -68.51M | -26.01M |
| CashFlowFromContinuingOperatingActivities | -36.39M | 21.55M | -68.51M | -26.01M |
| TaxesRefundPaid | 197.00K | 78.00K | -96.00K | -117.00K |
| InterestReceivedCFO | 3.25M | 2.59M | 106.00K | 5.00K |
| InterestPaidCFO | -770.00K | -789.00K | -3.76M | -2.25M |
| ChangeInWorkingCapital | -13.26M | 48.96M | -4.99M | 25.01M |
| ChangeInOtherWorkingCapital | -13.26M | 48.96M | -4.99M | 25.01M |
| OtherNonCashItems | -2.81M | -6.01M | 1.65M | 1.89M |
| StockBasedCompensation | 2.54M | 3.11M | 2.87M | 6.22M |
| DeferredTax | -197.00K | -78.00K | 96.00K | 117.00K |
| DeferredIncomeTax | -197.00K | -78.00K | 96.00K | 117.00K |
| DepreciationAmortizationDepletion | 2.76M | 2.51M | 2.52M | 2.33M |
| DepreciationAndAmortization | 2.76M | 2.51M | 2.52M | 2.33M |
| Depreciation | 2.76M | 2.51M | 2.52M | 2.33M |
| OperatingGainsLosses | -345.00K | -1.08M | -2.71M | 1.58M |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | 8.00K | 217.00K |
| GainLossOnInvestmentSecurities | -345.00K | -953.00K | -2.71M | 1.88M |
| GainLossOnSaleOfBusiness | 0.00 | -131.00K | 0.00 | -514.00K |
| NetIncomeFromContinuingOperations | -27.76M | -27.73M | -64.20M | -60.80M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PRQR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|